An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Formulation of MLN9708 Administered Weekly in Adult Patients With Relapsed or Refractory Light-Chain (AL) Amyloidosis Who Require Further Treatment

Name: An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Formulation of MLN9708 Administered Weekly in Adult Patients With Relapsed or Refractory Light-Chain (AL) Amyloidosis Who Require Further Treatment
Creator: Vivli
Published: 2025-10-01 20:54:07
License: 暂无描述

DataCite Commons2025-10-01 更新2026-05-07 收录

下载链接：

https://search.vivli.org/doiLanding/studies/00007110/isLanding

下载链接

链接失效反馈

官方服务：

资源简介：

This study will include participants with previously treated systemic relapsed or refractory light-chain (AL) amyloidosis who require further therapy and will be aimed at determining the safety profile and the maximum tolerated dose/recommended phase 2 dose of MLN9078 (Ixazomib) administered orally.

提供机构：

Vivli

创建时间：

2021-05-06